10/31/2026
Among patients listed for , those with had greater comorbidity burden at listing, including more diabetes and kidney dysfunction, despite identical biologic Model for End-Stage Liver Disease scores compared with matched patients without MASH. They also had worse long-term overall, waiting-list, and posttransplant mortality, indicating that comorbidities may contribute importantly to outcomes beyond liver disease severity alone.
This cohort study examines the comorbidities and long-term outcomes associated with metabolic dysfunction–associated steatohepatitis (MASH) in patients on the liver transplant waiting list.